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Abstract
Background: We use the example of the Gojjam Lymphoedema Best Practice Trial (GoLBeT), a pragmatic trial in a
remote rural setting in northern Ethiopia, to extract lessons relevant to other investigators balancing the demands
of practicality and community acceptability with internal and external validity in clinical trials.
Methods: We explain in detail the preparation for the trial, its setting in northern Ethiopia, the identification and
selection of patients (inclusion and exclusion criterion, identifying and screening of patients at home, enrollment of
patients at the health centres and health posts), and randomisation.
Results: We describe the challenges met, together with strategies employed to overcome them.
Conclusions: Examples given in the previous section are contextualised and general principles extracted where
possible. We conclude that it is possible to conduct a trial that balances approaches that support internal validity
(e.g. careful design of proformas, accurate case identification, control over data quality and high retention rates) with
those that favour generalisability (e.g. ‘real world’ setting and low rates of exclusion). Strategies, such as Rapid Ethical
Assessment, that increase researchers’ understanding of the study setting and inclusion of hard-to-reach participants
are likely to have resource and time implications, but are vital in achieving an appropriate balance.
Trial registration: ISRCTN67805210, registered 24/01/2013.
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Background
Randomized controlled trials (RCTs) are the cornerstone
of evidence-based decision making and are considered
the ‘gold standard’ for clinical research in both low- and
high-income countries. In recent years, a movement
towards health care decision-making that is more
informed by evidence has boosted clinical trials [1].
RCTs are needed globally to reduce disease burdens by
informing the development of safe and effective
treatment and prevention strategies [2]. However,
although developing countries bear the largest burden of
disease and high incidence rates, few RCTs are con-
ducted in such settings [3]. RCTs are critically important
for developing countries, not just for their potential to
improve health by establishing the true effectiveness of
new interventions [2], but also for their potential to
build health research capacity [4].
In resource limited countries like Ethiopia, the human
and material resources available to ensure a high level of
internal validity through design, management, and oper-
ation of clinical trials lag behind those of wealthier
nations [2]. The low number of trials in such countries
has also been attributed to issues such as difficulty
obtaining meaningful informed consent [5] and
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balancing risks, benefits, compensation and the potential
for unintended inducement among extremely poor pop-
ulations in the context of poor health infrastructure and
considerable socio-economic and cultural divides [6].
Many trials conducted in low income settings in the past
were designed by experts based in higher-income coun-
tries because of a lack of trained personnel and expertise
locally [7].
One important response to this lack of expertise is to
draw lessons and disseminate experience from the few
trials that are conducted in these settings. Here, we draw
examples from ‘GoLBeT’ (the Gojjam Lymphoedema
Best Practice Trial), a pragmatic trial among podoconio-
sis patients in a remote rural setting in northern
Ethiopia. Podoconiosis is a slowly progressive geochem-
ical lymphoedema associated with long-term barefoot
exposure to volcanic soils in tropical highland areas [11].
It results in significant social [12], physical [13] and
economic [14] burdens to patients, and hinders develop-
ment of affected communities. GoLBeT was designed to
evaluate the effectiveness of a simple foot hygiene pack-
age in reducing acute dermatolymphangioadenitis
(ADLA), one of the most common and disabling conse-
quences of podoconiosis [13]. The results were intended
to fill a gap in evidence and inform government policy
in Ethiopia and potentially in other endemic countries.
Pragmatic trials measure effectiveness of an intervention
in routine practice [8], so external validity is a high
priority. GoLBeT aimed to generate generalizable data
with high utility for policy makers without significant
comprise of internal validity [9]. Here, we explain in de-
tail the preparation for the trial, its setting in northern
Ethiopia, the identification and selection of patients (in-
clusion and exclusion criterion, identifying and screening
of patients at home, enrollment of patients at the health
centres and health posts), and randomisation. Through
this, we aim to identify lessons that may be of use to
others trying to balance internal and external validity [9]
in pragmatic trials in similar settings.
Methods
Trial background and governance
GoLBeT was a pragmatic randomized controlled trial of
podoconiosis lymphoedema management (ISRCTN67
805210). The trial was funded by the UK Joint Global
Health Trials initiative in 2013. The protocol, including
numbers and dates of all ethical approvals, has been
published [10]; in essence, the trial compared patients
randomized to the intervention arm (who were trained
to self-care using a hygiene and foot care intervention
which comprised use of soap, Whitfield ointment, ban-
dages, socks and shoes, exercise and elevation) with pa-
tients randomized to the control arm, who were
followed quarterly but received no intervention until the
trial was completed. The primary outcome was reduc-
tion in frequency of ADLA episodes. Patients in both
groups filled in a monthly primary outcome diary and
Case Report Forms (CRFs) were completed at 3-monthly
intervals.
Trial setting and participants
The trial was conducted in Aneded district, East Gojam
Zone, Amhara regional state (Fig. 1). There are 19
kebeles (sub-districts) in Aneded district (Fig. 2), which
is 18 km from the zonal capital, Debre Markos, where
the trial field coordination office was located [11]. Debre
Markos is 305 km from Addis Ababa, a drive of approxi-
mately six hours which crosses the Blue Nile Gorge. At
the time of this trial, no formal government or private
treatment for podoconiosis was available within Aneded
district. Within the district, there are two health centres,
and each kebele has a health post. Reaching these health
posts could take up to two hours from the asphalt in the
dry season, and longer in the rainy season. We made the
decision not to include the most remote kebele (Mal-
gash, 19 in Fig. 2) even though many patients were regis-
tered there, because access entailed a 1.5 h drive and
then a 1.5 h walk. However, patients in Malgash were
given education about podoconiosis and three months’
treatment supplies, at the close of the trial.
Inclusion and exclusion criteria are detailed in the
protocol [10], and their application resulted in exclusion
of only 19 of 1339 patients screened.
External support and monitoring
The trial coordinator and data manager spent two
weeks at the KWTRP Clinical Trials Facility during
the preparatory period. They were given hands-on
training in several important aspects of trial manage-
ment including development of Standard Operating
Procedures (SOPs), logs, forms and master files; use
of GPS; handling of the intervention product; Good
Clinical Practice (GCP) training of field staff; manage-
ment of hard-copy data; OpenClinica and other data-
base development. Trial monitoring site visits were
conducted by staff of the KWTRP Clinical Trials Fa-
cility and the Nuffield Department of Tropical Medi-
cine, Oxford University. A Trial Preparation Visit was
made in April 2013, a Site Initiation Visit in Decem-
ber 2014, Routine Monitoring Visits were made in
March 2014 and December 2015, and a Close Out
Visit in May 2017. These visits and a series of Skype
calls aimed to review protocol fidelity and regulatory
compliance.
Development of trial Proformas
Under guidance from the KWTRP Clinical Trials Facil-
ity, SOPs were developed by the trial coordinator, the
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data manager (both based in Ethiopia) and the UK-
based trial principal investigator through email
exchanges, weekly Skype meetings and quarterly face-
to-face meetings. Information gathered through a
Rapid Ethical Assessment [12] was used to develop
the patient information sheet and informed consent
forms. Meetings to explain the trial were held with
district Health Office personnel and with larger gath-
erings (including administrative, education, agriculture
and religious leaders and Health Extension Workers
from kebeles selected for the study). These aimed to
disseminate accurate information about the trial
through the district and to garner support of the vari-
ous departments to ensure the smooth conduct of the
trial.
CRFs were prepared for baseline, 3, 6, 9 and
12 months, according to the data collection schedule
described in the protocol [10]. These were made eas-
ily distinguishable through different coloured covers
(white, blue, green, purple and yellow, respectively).
In addition, a patient-completed pictorial diary was
developed. Patients were trained to complete the diary
by inserting a mark in the appropriate column for
that day – either one headed by a picture of a person
in bed with ADLA or one headed by a person work-
ing in the field (both men and women work in the
field in this part of rural Ethiopia). The diary was
tested for acceptability, feasibility and accuracy using
patient interviews and assessment of patient records
against health professional diagnoses. The Ethiopian
calendar was used for data collection and entry.
Recruitment and training of field staff
Twenty Community Podoconiosis Agents (CPAs), and
two CPA supervisors; ten data collectors and two data
collector supervisors were recruited and given five
days’ training on GCP, screening, informed consent
administration and enrollment (all field staff ); on data
collection, data management and data security proce-
dures (data collectors and their supervisors); and on
intervention training, outcome diary checking and ad-
herence monitoring (CPAs). Because of delays in gain-
ing ethical approval, another five days’ refresher
training was given immediately before enrollment
commenced.
Database development
After consideration of continuity of power supply,
internet access, servicing, security and protection
from water damage, the server was located in the
IOCC office in Addis Ababa rather than in Debre
Markos. An OpenClinica template was created and
tested prior to data entry. Difficulties exporting data
to other programmes were resolved. Two data entry
clerks were given three days’ training to enter base-
line data from the Case Report Forms. Access to the
database from the KWTRP Clinical Trials Facility was
tested several times before data entry was
commenced.
Ethical and regulatory considerations
Ethical approval required three serial applications.
Approval from the School of Public Health was a
Fig. 1 Map of Amhara Region, showing location of Aneded district
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prerequisite of applying to the Addis Ababa Univer-
sity Institutional Review Board (IRB). Approval from
the IRB was necessary before the process could con-
tinue with the national regulator and the national
ethics review committee in Ethiopia. Regulatory ap-
proval elicited questions about the need for purchase
approval for the intervention product even though it
was already publicly available. Approval at national
level was delayed because this committee was dis-
banded in the week following submission of the GoL-
Bet dossier, and was not reconvened for several
months. Another reason for the delay at national level
was loss of the study documents submitted for
review, necessitating resubmission. Approval was
eventually given at the start of the rainy season, so
the decision was made to postpone screening until
after the rainy season so as to maximise enrollment.
A six-month extension to the project was requested
and granted by the funding body.
Results
Listing and screening
Listing of patients started in the nine most accessible
kebeles of Aneded district (kebeles 7–14 and 16, Fig. 2).
In each of these kebeles, the two Health Extension
Workers (local women with one year’s training in dis-
ease prevention and health promotion) were asked to list
all people they knew to have leg swelling. The screening
team (data collectors, data collector supervisors and the
data manager) visited each potential participant at home
and after oral informed consent, made a preliminary
check against the inclusion and exclusion criteria that
could be assessed verbally. Each person’s willingness to
be considered for the trial was assessed, and those that
wished to be considered were given an appointment for
an enrollment visit at their nearest health post or health
centre. Geographic Information System coordinates of
the patient’s house were recorded, to be used (if the pa-
tient went forward to randomisation) to avoid
Fig. 2 Map of Aneded district showing kebeles. Rounds 1 and 2 recruitment took place in kebeles 7–14 and 16, and round 3 in kebeles 1–6, 15, 17
and 18
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randomisation of neighbours to different intervention
groups. The screening team used a snowball approach,
asking about other potential patients while in a given
community, and visiting individuals suggested.
Enrollment
Enrollment took place at government health posts and
health centres. The enrollment team (data collectors,
data collector supervisors, CPAs, CPA supervisors, the
local safety monitor, the data manager, the trial coordin-
ator and a laboratory technician) welcomed patients,
gave group information about the trial and obtained in-
dividual informed consent. The consent form was signed
by the participant if they were able to write. For those
unable to write, they added their thumbprints and an
independent witness signed to confirm the thumbprint
and that all questions had been answered to the partici-
pant’s satisfaction, as agreed by the IRBs. They then
made a full assessment of eligibility against the inclusion
and exclusion criteria, including an immunochromato-
graphic test. A unique study identification number was
issued, and a photo taken for a trial identity card. The
baseline Case Report Form was administered, and in-
cluded socio-demographic information; frequency and
duration of ADLA; Dermatology Life Quality Index;
WHO-Disability Assessment Schedule; perceived stigma;
and clinical signs including disease stage, foot and leg
circumference, presence of mossy changes, wounds and
entry lesions. Once this had been completed, the partici-
pant was informed that the result of randomization
would be delivered to them at home and was given a
copy of the information sheet and signed consent form
to take home.
Recruitment
Given prevalence of podoconiosis in Amhara region of
3.9% and a district population over 100,000 (suggesting
an adult population over 50,000), we originally assumed
we would be able to recruit 680 patients for the trial
using the nine most accessible kebeles in the district
(numbers 7 to 14 and 16 in Fig. 2). However, in Decem-
ber 2014 and January 2015 we enrolled just 425 patients
from these kebeles. After screening, rates of attendance
at enrollment varied considerably from kebele to kebele,
from 43% to over 90%. Feedback from field staff sug-
gested this was predominantly due to potential partici-
pants being involved in the harvest and in compulsory
local environmental protection campaigns. Very few
(three) patients discussed the trial information and de-
cided not to participate. However, in one kebele, misin-
formation spread by one individual alarmed patients.
Acting on suggestions made during the Rapid Ethical
Assessment [12] about quashing community rumours,
the trial coordinator and data manager arranged an
emergency kebele meeting to negotiate with gatekeepers
and prevent further rumours being spread. The team
made the decision to offer further enrollment sessions in
the original 9 kebeles and to extend listing and screening
to 9 of the 10 less-accessible kebeles. Using this
approach, a further 271 patients were enrolled to reach
the required sample size. The numbers enrolled are
shown in Fig. 3.
Randomisation
During a preparatory meeting with District Health Office
personnel, concerns were raised about the use of
randomization and the existence of a control group. The
Rapid Ethical Assessment had covered these areas, and
local parallels to randomization and delayed treatment
to trial groups had been suggested. These included the
random methods used to disburse sums from traditional
savings systems such as ‘Equb’ or decide whose turn it is
to graze cattle, and comparisons of traditional and mod-
ern fertilizers used by agricultural development workers.
These illustrations were used to explain the trial process




Aneded district is a challenging setting for any research
study, and this trial, which required 12 intervention
visits and 4 data collection follow-ups for each patient,
was demanding for participants, the trial team and those
managing logistics. This district was chosen as being
representative of districts into which treatment might be
expanded in real life, and because no treatment services
had been established within the district prior to the trial.
Aneded district was an appropriate choice, given that
pragmatic trials such as GoLBet are designed to test the
effectiveness of an intervention in the real world [13].
When the real world of patients is a remote, low-
Fig. 3 Overall listing, screening and enrollment flow
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resource setting such as Gojjam, carrying out a high
quality trial to GCP standards will demand considerable
commitment from the trial team. Field staff will need
physical stamina, ingenuity and resilience. While clear
schedules and timelines are essential, the trial team will
also need to be adaptable and contingency funding may
be necessary to cover additional transport costs, for
example when roads became impassable or bridges were
washed away.
Regulatory requirements
Trial registration was completed in January 2014 within
four months of confirmation of funding. Gaining ethical
and regulatory approvals was more complex, partly be-
cause this had to be done consecutively rather than in
parallel. Delays introduced by the ethical review process
have previously been noted to be significant bottlenecks
to research [7], and our experience confirms this. Devel-
oping ethical review capacity and streamlining review
processes will be vital in overcoming delays like this in
future. Even though regulatory requirements state that
IRB members will make field visits to monitor trial pro-
gress and participant safety, these visits rarely happen in
practice. We were aware of the value of sharing experi-
ence of this rare pragmatic trial with regulatory author-
ities, and so funded a two-member team from the
National Research Ethics Review Committee to visit the
study site.
Case identification
We relied on lists compiled by Health Extension
Workers to identify potential lymphoedema patients. Pa-
tients with podoconiosis often experience considerable
stigmatisation [14, 15], so it is important that researchers
approach patients through trusted members of the com-
munity such as health workers [16, 17]. Since podoco-
niosis has not until recently been included in health
curricula, questions around the validity of identification
by community workers exist. Earlier studies in Ethiopia
have demonstrated that, in areas of high podoconiosis
endemicity, health workers with very little training can
identify patients accurately [18]. However, in areas of
lower endemicity, such as North West Cameroon, the
positive predictive value of community health worker
identification is lower [19]. We used a wide case defin-
ition for the listing stage of the recruitment process, and
then used a two-stage process (screening and then en-
rollment) to ensure that only eligible adult podoconiosis
patients were invited to participate. Patients with leg
swelling identified by Health Extension Workers over-
whelmingly had podoconiosis; there were no positive
immunochromatographic tests for lymphatic filariasis.
The most common reason that patients screened were
not enrolled was that they had stage 1 disease (551/1339
screened), that is, their leg swelling resolved overnight
[20].
Patient recruitment
Patient recruitment is frequently a challenge for RCTs,
with UK funding bodies reporting less than one third of
trials meeting their original targets [21]. A systematic re-
view performed to identify interventions to improve re-
cruitment included 45 trials [22]. Of these, only one trial
had a single site in a low-income setting (the
Philippines), and, unsurprisingly, few of the interven-
tions were relevant to a remote rural setting like Gojjam.
We experienced lower-than-anticipated recruitment in
the nine most accessible kebeles, and used results from
the Rapid Ethical Assessment [12] to mitigate this by
quashing negative rumours and extending recruitment
to more remote kebeles. The move to quash rumours
might be construed as a departure from pragmatism, but
as a team we considered the need to complete recruit-
ment to outweigh efforts to preserve pragmatism during
trial set-up. Rapid Ethical Assessment is increasingly
used to ‘map’ the ethical terrain of a research setting
prior to recruitment of participants [16, 17, 23, 24], and
has been demonstrated to improve recruitment and re-
tention rates in longitudinal studies [25]. We therefore
strongly recommend the use of Rapid Ethical Assess-
ment prior to complex studies including trials, in
research-naïve settings.
Data analysis
The Ethiopian calendar is a solar calendar similar to the
Julian calendar. There are twelve months each of 30 days,
and one month of 5 days (6 in a leap year). The Ethiop-
ian calendar runs over 7 years behind the Gregorian
(‘Western’) calendar, so neither years nor months nor
days synchronize between the two calendars. Calendar
issues regularly cause difficulties with longitudinal stud-
ies using Western-developed software. The GoLBeT
team made the decision to collect and enter data using
the Ethiopian calendar, and during analysis to use an al-
gorithm to convert dates to the Gregorian calendar. This
approach has been used by other research teams in
Ethiopia to overcome date inconsistencies [26].
In order to conduct a high quality trial whose results
are generalizable to the real world setting, a balance
must often be struck between internal and external val-
idity. Through examples that arose during GoLBeT, we
demonstrate that this need not always represent a trade-
off: it is possible to achieve high standards in both
spheres, but this is likely to require additional time (for
example, to conduct Rapid Ethical Assessment prior to
the trial) and resources (for example, to ensure the same
quality of follow up and data collection in the most
remote settings).
Molla et al. BMC Medical Research Methodology  (2018) 18:26 Page 6 of 8
Abbreviations
ADLA: acute dermatolymphangioadenitis; CPA: Community Podoconiosis
Agents; CRF: Case Report Form; GCP: Good Clinical Practice; GoLBeT: Gojjam
Lymphoedema Best Practice Trial; IOCC: International Orthodox Christian
Charities; IRB: Institutional Review Board; ISRCTN: International Standard
Randomised Controlled Trial Number; KWTRP: KEMRI/Wellcome Trust
Research Programme; RCT: Randomised Controlled Trial; SOP: Standard
Operating Procedure; UK: United Kingdom
Acknowledgements
We are very grateful for logistic management provided by International
Orthodox Christian Charities, Ethiopia, in particular Dr. Seifu Tirfie, Hari Desta,
Tsige Amberbir, Wolela Woldegebriel, and the team of dedicated drivers. We
thank Dr. Worku Mekonnen and Dr. Biruk Lambiso for acting as Local Safety
Monitors, and officials at the Woreda Health Office in Amber for their
assistance with approach to patients in Aneded woreda. We thank the Trial
Steering Committee (including Prof. Richard Hayes, Dr. Sarah Joseph and Dr.
Abraham Aseffa) for their advice and support throughout the study.
Funding
This study was funded via the Joint Global Health Trials Initiative by the
Wellcome Trust, the UK Medial Research Council and UK AID (MR/K007211/1;
WT099946MA). This UK funded award is part of the EDCTP2 programme
supported by the European Union.
Availability of data and materials
Data from the GoLBeT trial are available to researchers under the terms of
the GoLBeT Data Sharing Protocol, on the public webpage of the GoLBeT
trial (http://www.podo.org/research/current/golbet-trial/).
Authors’ contributions
This sub-study was conceived by MM, MN and JB, while EK, PN, GD and FE
developed the original protocol. Regulatory approvals were secured by GD
and HN. Data were obtained by MM and HN with the aid of a team super-
vised by MM. The trial was monitored by EK. MM wrote the first draft of the
article, which was revised by GD and commented on by all authors. All au-
thors read and approved the final manuscript.
Ethics approval and consent to participate
The trial was approved by the IRB of the College of Health Sciences, Addis
Ababa University (meeting number 056/2014; protocol number 071/13/SPH;
approval date: 12/01/2014), the National Ethical Review Committee of the
Ethiopian Science and Technology Agency (approval number 3–1/794/06;
approval date: 02/06/2014), the Food, Medicine and Health Care
Administration Authority (reference number 02/6–1/05/39; approval date: 09/
04/2014) and the Research Ethics and Governance Committee of Brighton &
Sussex Medical School (approval number 13/107/DAV; approval date: 12/08/
2014). Initial oral consent was sought for screening of those who fulfilled
inclusion and exclusion criteria at this visit. Patients who then attended an
enrolment appointment at a nearby health post were given further
information about the trial (taking into account the community’s expressed
preferences for content and delivery of information elicited during Rapid
Ethical Assessment). Individual informed consent was provided, either signed
by the participant or thumbprinted and then signed by an independent




The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Centre for Environment and Development Studies, Addis Ababa University,
Addis Ababa, Ethiopia. 2Wellcome Trust Centre for Global Health Research,
Brighton & Sussex Medical School, University of Sussex, Brighton BN1 9PX,
UK. 3KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya. 4School of
Public Health, Addis Ababa University, Addis Ababa, Ethiopia. 5Centre for
Tropical Medicine & Global Health, University of Oxford, Oxford, UK.
Received: 24 October 2017 Accepted: 27 February 2018
References
1. Domanski M, McKinlay S. Successful Randomized Trials: A Handbook for the
21st Century. Philadelphia: Lippincott Williams & Wilkins; 2009.
2. Lang T, White N, Tran H, Farrar J, Day N, Fitzpatrick R, Angus B, Denis
D, Merson L, Cheah P, et al. Clinical research in resource-limited
settings: enhancing research capacity and working together to make
trials less complicated. PLoS Negl Trop Dis. 2010;4(6):e619.
3. Berkley J. Randomised trials in developing countries. Arch Dis Child. 2014;99:
607–8.
4. Franzen S, Chandler C, Lang T. Health research capacity development in
low and middle income countries: reality or rhetoric? A systematic
meta-narrative review of the qualitative literature. BMJ Open. 2017;7(1):
e012332.
5. Moodley K, Pather M, Myer L. Informed consent and participant perceptions
of influenza vaccine trials in South Africa. J Med Ethics. 2005;31:727–32.
6. Joseph P, Caldwell P, Tong A, Hanson C, Craig J. Stakeholder views of
clinical trials in low- and middle-income countries: a systematic review.
Paediatrics. 2016;137(2):e20152800.
7. Franzen S, Chandler C, Enqueselassie F, Siribaddana S, Atashili J, Lang T.
Understanding the investigators: a qualitative study investigating the
barriers and enablers to the implementation of local investigator-initiated
clinical trials in Ethiopia. BMJ Open. 2013;3(11):e003616.
8. Roland M, Torgerson D. Understanding controlled trials: what are pragmatic
trials? Br Med J. 1998;316:285.
9. Godwin M, Ruhland L, Casson I, MacDonald S, Delva D, Birtwhistle R,
Lam M, Seguin R. Pragmatic controlled clinical trials in primary care: the
struggle between external and internal validity. BMC Med Res
Methodol. 2003;3(28).
10. Negussie H, Molla M, Fegan G, Njuguna P, Enqueselassie F, McKay A,
Newport M, Lang T, Davey G. GoLBeT [Gojjam Lymphoedema best
practice trial]: description of study protocol for a randomised controlled
trial of effectiveness of treatment for podoconiosis (non-filarial
elephantiasis). Trials. 2015;16:8.
11. Tomczyk S, Tamiru A, Davey G. Addressing the neglected tropical disease
Podoconiosis in northern Ethiopia: lessons learned from a new community
Podoconiosis program. PLoS Negl Trop Dis. 2012;6(3).
12. Negussie H, Addissie A, Addissie T, Davey G. Preparing for and executing a
randomised controlled trial of Podoconiosis treatment in northern Ethiopia:
the utility of rapid ethical assessment. PLoS Negl Trop Dis. 2016;10(3):
e0004531.
13. Ford I, Norrie J, Trials P. N Engl J Med. 2016;375:454–63.
14. Tora A, Franklin H, Deribe K, Reda A, Davey G. Extent of podoconiosis-
related stigma in Wolaita zone, southern Ethiopia: a cross-sectional study.
Springerplus. 2014;3:647.
15. Deribe K, Tomczyk S, Mousley E, Tamiru A, Davey G. Stigma towards
a neglected tropical disease: felt and enacted stigma scores among
podoconiosis patients in northern Ethiopia. BMC Public Health. 2013;
13:178.
16. Tekola F, Bull S, Farsides B, Newport M, Adeyemo A, Rotimi C, Davey G.
Impact of social stigma on the process of obtaining informed consent for
genetic research on podoconiosis: a qualitative study. BMC Med Ethics.
2009;10:e13.
17. Kengne-Ouafu J, Nji T, Tantoh W, Nyoh D, Tendongfor N, Enyong P, MJ N,
Davey G. Perceptions of consent, permission structures and approaches to
the community: a rapid ethical assessment performed in north West
Cameroon. BMC Public Health. 2014;14:1026.
18. Desta K, Ashine M, Davey G. Predictive value of clinical assessment of
patients with podoconiosis in an endemic community setting. Trans R Soc
Trop Med Hyg. 2007;101:621–3.
19. Wanji S, Kengne-Ouafu J, Datchoua-Poutcheu F, Njouendou A, Tayong
D, Sofeu-Feugaing D, Amvongo-Adija N, Fovennso B, Longang-
Tchounkeu Y, Tekola Ayele F, et al. Detecting and staging podoconiosis
cases in north West Cameroon: positive predictive value of clinical
screening of patients by community health workers and researchers.
BMC Public Health. 2016;16:997.
Molla et al. BMC Medical Research Methodology  (2018) 18:26 Page 7 of 8
20. Tekola F, Ayele Z, HaileMariam D, Fuller C, Davey G. Development and
testing of a de novo clinical staging system for podoconiosis (endemic non-
filarial elephantiasis). Tropical Med Int Health. 2008;13(10):1277–83.
21. McDonald A, Knight R, Campbell M, Entwhistle V, Grant A, Cook J, Elbourne
D, Francis D, Garcia J, Roberts I, et al. What influences recruitment to
randomised controlled trials? A review of trials funded by two UK funding
agencies. Trials. 2006;7(9).
22. Treweek S, Lockhart P, Pitkethly M, Cook J, Kjeldstrom M, Johansen M,
Taskila T, Sullivan F, Wilson S, Jackson C, et al. Methods to improve
recruitment to randomised controlled trials: Cochrane systematic review
and meta-analysis. BMJ Open. 2013;3:e002360.
23. Kengne-Ouafu J, Millard J, Nji T, Tantoh W, Nyoh D, Tendongfor N, Enyong
P, MJ N, Davey G, Wanji S. Understanding of research, genetics and genetic
research in a rapid ethical assessment in north-West Cameroon. Int Health.
2015; https://doi.org/10.1093/inthealth/ihv034.
24. Tekola F, Bull S, Farsides B, Newport M, Adeyemo A, Rotimi C, Davey G.
Tailoring consent to context: designing an appropriate consent process
for a biomedical study in a low income setting. PLoS Negl Trop Dis.
2009;3(7):e482.
25. Addissie A, Abay S, Feleke Y, Newport M, Farsides B, Davey G. Cluster
randomized trial assessing the effects of rapid ethical assessment on
informed consent comprehension in a low-resource setting. BMC Med
Ethics. 2016;17(40).
26. Little A, Medhanyie A, Yebyo H, Spigt M, Dinant G, Blanco R. Meeting
community health worker needs for maternal health care service
delivery using appropriate mobile Technologies in Ethiopia. PLoS One.
2013;9(1):10.1371.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Molla et al. BMC Medical Research Methodology  (2018) 18:26 Page 8 of 8
